Abstract:BackgroundPrevious elegant studies performed in the fission yeast Schizosaccharomyces pombe have identified a requirement for heterochromatin protein 1 (HP1) for spindle pole formation and appropriate cell division. In mammalian cells, HP1γ has been implicated in both somatic and germ cell proliferation. High levels of HP1γ protein associate with enhanced cell proliferation and oncogenesis, while its genetic inactivation results in meiotic and mitotic failure. However, the regulation of HP1γ by kinases, critic… Show more
“…An enhanced effect of the combination to inhibit PDAC growth is also observed with 3D spheroid and organoid cultures, as well as xenografts in vivo (Figure 3). This is consistent with the fact that these targets are in the same biological pathway that aids to the proper completion of mitosis [12]. Upon cell cycle arrest caused by AurkA inhibition, the mitotic machinery is exposed longer to targeting by the H3K9me pathway, which during mitosis regulates centromere structure.…”
Section: Discussionsupporting
confidence: 75%
“…Western blots were performed as previously described [12]. Membranes were blocked in 3% BSA/TBST and incubated overnight at 4°C with primary antibody (Supplementary Table 1).…”
Section: Methodsmentioning
confidence: 99%
“…We have shown that a member of the methyl lysine 9 histone 3 (H3K9me) pathway, HP1γ (CBX3), is phosphorylated by AurkA to support normal mitotic progression [12]. The K9H3me histone mark to which HP1 binds is established by the H3K9 histone methyltransferases (HMTs) G9a, GLP, SUV39H1 and SUV39H2.…”
The current integrative pathobiological hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylation-based epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in 3D spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G2/M after targeting Aurora kinase A, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, this data describes for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic-epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies, as well as biomedical relevance.
“…An enhanced effect of the combination to inhibit PDAC growth is also observed with 3D spheroid and organoid cultures, as well as xenografts in vivo (Figure 3). This is consistent with the fact that these targets are in the same biological pathway that aids to the proper completion of mitosis [12]. Upon cell cycle arrest caused by AurkA inhibition, the mitotic machinery is exposed longer to targeting by the H3K9me pathway, which during mitosis regulates centromere structure.…”
Section: Discussionsupporting
confidence: 75%
“…Western blots were performed as previously described [12]. Membranes were blocked in 3% BSA/TBST and incubated overnight at 4°C with primary antibody (Supplementary Table 1).…”
Section: Methodsmentioning
confidence: 99%
“…We have shown that a member of the methyl lysine 9 histone 3 (H3K9me) pathway, HP1γ (CBX3), is phosphorylated by AurkA to support normal mitotic progression [12]. The K9H3me histone mark to which HP1 binds is established by the H3K9 histone methyltransferases (HMTs) G9a, GLP, SUV39H1 and SUV39H2.…”
The current integrative pathobiological hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylation-based epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in 3D spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G2/M after targeting Aurora kinase A, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, this data describes for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic-epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies, as well as biomedical relevance.
“…Previous reports have detected high levels of HP1γ protein associated with enhanced cell proliferation and oncogenesis in colon, breast, and cervical cancers (Takanashi et al , ; Abe et al , ; Slezak et al , ). Also, HP1γ S83 was reported enriched at the mitotic spindle, suggesting an additional role in proper mitotic cell division (Grzenda et al , ). Our in vivo analysis indicated that terminally differentiated columnar absorptive enterocytes were devoid of HP1γ, while the expression was detectable in the basal level of the crypt that contained the proliferative cell compartment.…”
HP1 proteins are transcriptional regulators that, like histones, are targets for post-translational modifications defining an HP1-mediated subcode. HP1c has multiple phosphorylation sites, including serine 83 (S83) that marks it to sites of active transcription. In a guinea pig model for Shigella enterocolitis, we observed that the defective type III secretion mxiD Shigella flexneri strain caused more HP1c phosphorylation in the colon than the wild-type strain. Shigella interferes with HP1 phosphorylation by injecting the phospholyase OspF. This effector interacts with HP1c and alters its phosphorylation at S83 by inactivating ERK and consequently MSK1, a downstream kinase. MSK1 that here arises as a novel HP1c kinase, phosphorylates HP1c at S83 in the context of an MSK1-HP1c complex, and thereby favors its accumulation on its target genes. Genome-wide transcriptome analysis reveals that this mechanism is linked to up-regulation of proliferative gene and fine-tuning of immune gene expression. Thus, in addition to histones, bacteria control host transcription by modulating the activity of HP1 proteins, with potential implications in transcriptional reprogramming at the mucosal barrier.
“…It has been proposed that HP1α localizes to heterochromatin by binding to the tri-methylated tails of histone H3 at Lysine 9 (H3K9me3). [26][27][28] It has also been shown that Aurora B-mediated phosphorylation of the adjacent H3 serine 10 residues displaces HP1 binding from mitotic heterochromatin and forms part of a binary "methyl/phospho" switch that is critical for proper cell division in yeast 29 and mammalian cells. 30 In mammals, recruitment of the AuroB/AIM-1 kinase complex to HP1α sites in heterochromatin is reported to occur in G 2 and is important for the G 2 /M transition.…”
Section: Changes In Hp1α Dynamics In Escsmentioning
We recently reported that mouse embryonic stem cells (ESCs) in S/G 2 are more efficient at reprogramming somatic cells than ESCs at other stages of the cell cycle. We also provided evidence that DNA replication is induced in the nuclei of somatic partners upon fusion with ESC partners, and showed that this was critical for their conversion toward a pluripotent state.1 Here we have used counterflow centrifugal elutriation to enrich for ESCs at different cell cycle phases, so as to examine in detail the properties of S/G 2 phase cells. This revealed that the replication and organization of DAPI-intense heterochromatin in ESCs is unusual in two respects. First, replication of heterochromatin occurred earlier during S phase and was associated with precocious H3S10 phosphorylation. Second, heterochromatin protein 1 α (HP1α), which invariably marks DAPI-intense and H3K9me3-enriched pericentromeric domains in mouse somatic cells, 2 was not necessarily associated with these H3K9me3-enriched domains in undifferentiated ESCs. These data, which complement recent replication timing 3 and electron spectroscopic imaging (ESI) analyses, 4 suggest that heterochromatin is atypical in ESCs. Interestingly, as these unusual features were rapidly acquired by somatic nuclei upon ESC fusion-mediated reprogramming, our results suggest that fundamental changes in cell cycle structure and heterochromatin dynamics may be important for conferring pluripotency.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.